CAMBRIDGE, Mass., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Canaccord Genuity 33rd Annual Growth Conference. Craig Fraser, President of Aegerion, is scheduled to present on Thursday, August 15, 2013 at 9:00 a.m. ET.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Manager, Investor Relations 857-242-5024
Source:Aegerion Pharmaceuticals, Inc.